News from ptc therapeutics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 06, 2019, 08:00 ET PTC Therapeutics Celebrates the Fifth Anniversary of STRIVE Grant Awards by Announcing 2019 Award Winners

PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's 2019 global STRIVE Awards program, designed to support...

Aug 06, 2019, 16:01 ET PTC Therapeutics Reports Second Quarter 2019 Financial Results and Provides a Corporate Update

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the second quarter ending June 30, 2019....

Aug 05, 2019, 08:00 ET PTC Therapeutics Expands Presence in New Jersey by Securing State-of-the-Art Biologics Facility

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has signed a long-term lease agreement with Bristol-Myers Squibb Company (NYSE: BMY). Under...

Jul 31, 2019, 16:30 ET PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on July 26, 2019 it approved non-statutory stock options to purchase an aggregate of...

Jul 23, 2019, 08:00 ET PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2019 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2019...

Jul 01, 2019, 08:00 ET PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics

PTC Therapeutics, Inc. (NASDAQ: PTCT) and Odylia Therapeutics today announced a strategic collaboration to develop novel gene therapies in rare...

Jun 28, 2019, 06:40 ET PTC Provides Update on Translarna™ (ataluren) Application for Label Expansion

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

Jun 07, 2019, 13:31 ET PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental New Drug...

Jun 03, 2019, 08:00 ET PTC Therapeutics Promotes Emily Hill to Chief Financial Officer

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Emily Hill to Chief Financial Officer. Ms. Hill joined PTC Therapeutics in...

May 31, 2019, 16:30 ET PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 20, 2019 it approved non-statutory stock options to purchase an aggregate of 76,250 ...

May 30, 2019, 08:00 ET PTC Therapeutics to Participate at Upcoming Investor Conference

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Jefferies Healthcare Conference on...

May 20, 2019, 08:00 ET PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three funding recipients from PRIORITY, an annual program to support outstanding clinical...

May 09, 2019, 16:05 ET PTC Therapeutics and MRI Interventions Announce Strategic Investment

PTC Therapeutics, Inc. (NASDAQ: PTCT) and MRI Interventions, Inc. (OTCQB: MRIC) today announced a strategic equity investment, with PTC purchasing $4....

May 08, 2019, 08:00 ET PTC Therapeutics to Participate at Upcoming Investor Conferences

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Bank of America...

May 07, 2019, 01:00 ET Data from Pivotal FIREFISH and SUNFISH Studies Demonstrate Clinical Benefit of Risdiplam in Type 1, 2, & 3 Spinal Muscular Atrophy Patients

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced clinical data from the studies of FIREFISH and SUNFISH demonstrating the benefit of risdiplam...

May 03, 2019, 16:30 ET PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 23, 2019 it approved non-statutory stock options to purchase an aggregate of...

May 02, 2019, 16:01 ET PTC Therapeutics Reports First Quarter 2019 Financial Results and Provides a Corporate Update

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2019....

Apr 29, 2019, 09:18 ET Translarna™ (ataluren) is the First Therapy Approved in Brazil for Duchenne Muscular Dystrophy

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) has been granted marketing approval from the Brazilian National...

Apr 18, 2019, 08:00 ET PTC Therapeutics to Host Conference Call to Discuss First Quarter 2019 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2019 financial ...

Mar 04, 2019, 16:30 ET PTC Therapeutics to Participate at Upcoming Investor Conferences

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Cowen and Company...

Mar 04, 2019, 08:00 ET PTC to Expand Product Portfolio in Latin America with WAYLIVRA™

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its partner, Akcea Therapeutics, affiliate of Ionis Pharmaceuticals, received a positive...

Mar 01, 2019, 16:30 ET PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on February 25, 2019 it approved non-statutory stock options to purchase an aggregate of...

Feb 28, 2019, 16:01 ET PTC Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides a Corporate Update

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending...

Feb 25, 2019, 16:30 ET PTC Therapeutics Announces Partial Exercise of Underwriter's Option to Purchase Additional Shares

PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that the sole underwriter of its previously announced public offering of 6,720,000 shares of...

Feb 14, 2019, 08:00 ET PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2018 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end...